9-Oxo-10(9H)-acridineacetic acid , >98.0%(HPLC) , 38609-97-1

Synonym(s):
(9,10-Dihydro-9-oxo-10-acridinyl)acetic acid;10-(Carboxymethyl)-9(10H)acridone

CAS NO.：38609-97-1

Empirical Formula: C15H11NO3

Molecular Weight: 253.25

MDL number: MFCD00157050

EINECS: 634-833-1

PRODUCT Properties

• Melting point: ~289 °C (dec.)
• Boiling point: 486.6±34.0 °C(Predicted)
• Density: 1.362
• storage temp.: Sealed in dry,Room Temperature
• solubility: Aqueous Base (Slightly), DMSO (Slightly)
• form: Solid
• pka: 3.69±0.10(Predicted)
• color: Pale Yellow to Light Yellow
• λmax: 410nm(H2O)(lit.)
• BRN: 227508
• InChI: InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)
• InChIKey: UOMKBIIXHQIERR-UHFFFAOYSA-N
• SMILES: C1=C2C(N(CC(O)=O)C3=C(C2=O)C=CC=C3)=CC=C1

Description and Uses

9-Oxo-10(9H)-acridineacetic acid , also known as Cridanimod or XBIO-101, is a small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells.

9-Oxo-10(9H)-acridineacetic acid is a reagent for pre-column derivatization of amino acids for fluorescent determination in HPLC and it is also a building block in pharmaceutics.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• Hazard Codes: Xi
• Risk Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• RTECS: AR7190000
• HS Code: 2933.99.8290